Abstract
Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life- threatening cutaneous reaction, Stevens-Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.
| Original language | English |
|---|---|
| Pages (from-to) | 620-622 |
| Number of pages | 3 |
| Journal | British Journal of Haematology |
| Volume | 117 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2002 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Chronic myeloid leukaemia
- Skin
- Stevens-Johnson syndrome
- STI571
- Tyrosine kinase inhibitor
ASJC Scopus subject areas
- Hematology
Fingerprint
Dive into the research topics of 'Stevens-Johnson syndrome after treatment with STI571: A case report'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS